TLR-007
Anxiety Disorders
Phase 1/2Active
Key Facts
About Tilray
Tilray's mission is to be the world's leading cannabis-focused consumer branded goods and pharmaceutical company. Its key achievements include establishing one of the largest global footprints in cannabis cultivation and distribution, successfully merging with Aphria to create an industry leader, and building a clinical pipeline targeting serious conditions like glioblastoma and epilepsy. The company's strategy is to drive growth through its diversified portfolio—spanning cannabis, beverage alcohol, and wellness products—while investing in high-value pharmaceutical R&D to unlock long-term value from cannabinoid science.
View full company profileTherapeutic Areas
Other Anxiety Disorders Drugs
| Drug | Company | Phase |
|---|---|---|
| Anxiety Clinical Trials | Boston Clinical Trials | Not Specified (Typically Phase 2-3) |
| CTx-2103 | Cingulate Therapeutics | Pre-clinical |
| GABA-A PAM for Anxiety | Modulate Bio | Discovery |
| Anxiety Disorders Biomarker Services | The Siesta Group | Service Offering |
| LYT-300 | PureTech Health | Phase 1 |